Northwestern University, Chicago, IL, USA.
Pain Physician. 2010 Mar-Apr;13(2):157-65.
Intracranial neurostimulation for pain relief is most frequently delivered by stimulating the motor cortex, the sensory thalamus, or the periaqueductal and periventricular gray matter. The stimulation of these sites through MCS (motor cortex stimulation) and DBS (deep brain stimulation) has proven effective for treating a number of neuropathic and nociceptive pain states that are not responsive or amenable to other therapies or types of neurostimulation. Prospective randomized clinical trials to confirm the efficacy of these intracranial therapies have not been published. Intracranial neurostimulation is somewhat different than other forms of neurostimulation in that its current primary application is for the treatment of medically intractable movement disorders. However, the increasing use of intracranial neurostimulation for the treatment of chronic pain, especially for pain not responsive to other neuromodulation techniques, reflects the efficacy and relative safety of these intracranial procedures. First employed in 1954, intracranial neurostimulation represents one of the earliest uses of neurostimulation to treat chronic pain that is refractory to medical therapy. Currently, 2 kinds of intracranial neurostimulation are commonly used to control pain: motor cortex stimulation and deep brain stimulation. MCS has shown particular promise in the treatment of trigeminal neuropathic pain and central pain syndromes such as thalamic pain syndrome. DBS may be employed for a number of nociceptive and neuropathic pain states, including cluster headaches, chronic low back pain, failed back surgery syndrome, peripheral neuropathic pain, facial deafferentation pain, and pain that is secondary to brachial plexus avulsion. The unique lack of stimulation-induced perceptual experience with MCS makes MCS uniquely suited for blinded studies of its effectiveness. This article will review the scientific rationale, indications, surgical techniques, and outcomes of intracranial neuromodulation procedures for the treatment of chronic pain.
颅内神经刺激缓解疼痛最常通过刺激运动皮层、感觉丘脑、或导水管周围灰质和脑室周围灰质来实现。通过 MCS(皮层刺激)和 DBS(深部脑刺激)刺激这些部位已被证明对治疗多种神经性和伤害性疼痛状态有效,这些疼痛状态对其他治疗方法或类型的神经刺激没有反应或不适用。尚未发表确认这些颅内治疗方法疗效的前瞻性随机临床试验。颅内神经刺激与其他形式的神经刺激略有不同,因为其当前的主要应用是治疗医学上无法治疗的运动障碍。然而,越来越多地使用颅内神经刺激治疗慢性疼痛,特别是对于对其他神经调节技术没有反应的疼痛,反映了这些颅内手术的疗效和相对安全性。颅内神经刺激于 1954 年首次应用,是最早用于治疗对药物治疗有抵抗力的慢性疼痛的神经刺激之一。目前,有 2 种常用的颅内神经刺激方法来控制疼痛:皮层刺激和深部脑刺激。MCS 在治疗三叉神经病理性疼痛和丘脑疼痛综合征等中枢性疼痛综合征方面显示出特别的前景。DBS 可用于多种伤害性和神经性疼痛状态,包括丛集性头痛、慢性腰痛、失败的腰椎手术综合征、周围神经性疼痛、面部去传入性疼痛以及臂丛神经撕脱后的疼痛。MCS 具有独特的缺乏刺激诱导的知觉体验,这使其特别适合于其有效性的盲法研究。本文将回顾颅内神经调节程序治疗慢性疼痛的科学原理、适应证、手术技术和结果。